9-butyl-β-carboline | 21373-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-butyl-β-carboline
• 英文别名: 9-n-Butyl-β-carbolin；9-butyl-9H-β-carboline；9-n-butyl-β-carboline；9-Butylpyrido[3,4-b]indole
• CAS: 21373-42-2
• 化学式: C₁₅H₁₆N₂
• 分子量: 224.305
• InChiKey: MJPRNBOUZKLLOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 9-butyl-β-carboline 以 乙酸乙酯 为溶剂， 以85%的产率得到2-benzyl-9-butyl-β-carbolinium bromide
  参考文献：
  名称：

  Synthesis and structure–activity relationships of N2-alkylated quaternary β-carbolines as novel antitumor agents

  摘要：

  A series of novel N-2-alkylated quaternary beta-carbolines was synthesized by modification of position-1, 2,7 and 9 of beta-carboline nucleus with various alkyl and arylated alkyl substituents, and their cytotoxic activities in vitro and antitumor potencies in mice were evaluated. Compound 3m was found to be the most potent antitumor agent. SARs analysis revealed that (1) the substituents in position-2 and 9 of beta-carboline nucleus played a vital role in modulation of antitumor activity; (2) the benzyl and 3-phenylpropyl substituents in position-2 and 9 of beta-carboline ring were the optimal substituents giving rise to significant antitumor agent. These compounds might be a novel promising class of antitumor agents with clinical development potential. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.031
• 作为产物：
  描述：

  9H-吡啶[3,4-b]吲哚 、 1-碘丁烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以71%的产率得到9-butyl-β-carboline
  参考文献：
  名称：

  新型9-取代的β-咔啉衍生物的合成，急性毒性和抗肿瘤作用。

  摘要：

  分别从甜蜜素和色氨酸合成了一系列新颖的9-取代的β-咔啉衍生物。研究了这些化合物在体外的细胞毒活性。结果表明，大多数9-取代的β-咔啉衍生物的化合物在体外具有比其相应母体化合物更显着的细胞毒活性。还检查了选定的β-咔啉衍生物在小鼠中的急性毒性和抗肿瘤作用。结果表明，位置9处的短烷基或苄基取代基显着提高了抗肿瘤活性，位置3处的乙氧羰基或羧基取代基显着降低了这些β-咔啉衍生物的急性毒性和神经毒性。而且，与其他化合物相比，在第3位具有烷氧基羰基或羧基取代基且在第9位具有短烷基或苄基取代基的化合物均表现出更显着的抗肿瘤活性以及较低的急性毒性和神经毒性。发现分别在第9位和第3位具有正丁基和羧基取代基的化合物8c具有最高的抗肿瘤作用和最低的急性毒性和神经毒性。这些数据表明：（1）β-咔啉衍生物第9位和第3位的适当取代基可能在确定其增强的抗肿瘤活性以及降低的急性毒性和神经毒性作用方面起着至关重要的作用；

  DOI：

  10.1016/j.bmc.2004.06.038

文献信息

• Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo
  申请人：Wu Jialin

  公开号：US20090227619A1

  公开（公告）日：2009-09-10

  This invention relates to compounds of general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumour medicines and medicines used in treatment of tumour diseases in combination of light or radiation therapy.

  本发明涉及一般式（I）的化合物，其中R1、R2、R3、R4和R5如规范中所定义；用于它们的制备的中间体，制备方法和使用。本发明通过在β-噻吩类似物的母体结构的1、2、3、7和9位进行结构修饰，产生具有增强抗肿瘤活性和较低神经系统毒性的新的harmine衍生物。本发明的化合物可以轻松高产制备。它们可以用于制造各种抗肿瘤药物和用于结合光或放射治疗治疗肿瘤疾病的药物。
• B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Rommelspacher Hans

  公开号：US20100143474A1

  公开（公告）日：2010-06-10

  The embodiments relate to derivatives of 9-alkyl-β-carboline, their production and pharmaceutical compositions containing these 9-alkyl-β-carboline derivatives. Further, the use of 9-alkyl-β-carboline derivatives and pharmaceutical compositions for the treatment and prevention of movement disorders, neurodegenerative diseases, Alzheimer's disease and Parkinson's disease is described. Additionally, these effects can be utilized for the cultivation of cells such as dopaminergic cells or stem cells which shall be engrafted for the treatment of Parkinson's disease.

  本实施例涉及9-烷基-β-咔啉衍生物及其制备以及含有这些9-烷基-β-咔啉衍生物的药物组合物。此外，描述了利用9-烷基-β-咔啉衍生物和药物组合物治疗和预防运动障碍、神经退行性疾病、阿尔茨海默病和帕金森病的方法。此外，这些效果可用于培养细胞，如多巴胺能细胞或干细胞，这些细胞将被移植用于治疗帕金森病。
• BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Xinjiang Huashidan Pharmaceutical Research Co., Ltd.

  公开号：EP2924042A1

  公开（公告）日：2015-09-30

  Disclosed in the present invention are a bis-β-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-β-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-β-carboline compound is prepared through the condensation of β-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-β-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-β-carboline compound in preparing drugs resistant to tumours such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

  本发明公开了一种双-β-咔啉化合物及其制备方法、药物组合物和用途。其中，所述双-β-咔啉化合物及其药物盐为通式Ⅰ，双-β-咔啉化合物是通过β-咔啉中间体和二卤代烷烃缩合制备的。本发明还公开了一种药物组合物，该组合物包含有效剂量的式 I 所示的双-β-咔啉化合物和药学上可接受的载体，以及双-β-咔啉化合物在制备抗肿瘤药物中的用途，如黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔表皮癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌和结肠癌。
• HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF
  申请人：Xinjiang Huashidan Pharmaceutical Research Co., Ltd.

  公开号：EP1634881B1

  公开（公告）日：2011-07-27
• US8772311B2
  申请人：——

  公开号：US8772311B2

  公开（公告）日：2014-07-08